The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.

Prolongation of the reimbursement of VISMED® and VISMED® MULTI in France

The French Ministry of Health prolongued the partial reimbursement of VISMED® and VISMED® MULTI, both containing a sterile solution of preservative-free 0.18% sodium hyaluronate for ophthalmic use in the symptomatic treatment of the Dry Eye.

VISMED® is the only preservative-free sodium hyaluronate-based lubricant eye drops reimbursed in France.



Mannitol-stabilised high dose HA for sustained effect

OSTENIL® PLUS is a unique combination of natural high dose HA (2%) + mannitol.

Mannitol acts as a free radical scavenger which protects HA from rapid depolymerisation.

The formulation offers the possibility of reducing the number of intra-articular injections and increasing the intervals between injections. 

OSTENIL® PLUS reduces pain and improves function in osteoarthritis with very good tolerability.

Effective treatment with 1 to 3 injections of OSTENIL® PLUS

This new packaging design may not yet be available in your country 

pdf OSTENIL® PLUS Brochure
pdf OSTENIL® Line Brochure
pdf OSTENIL® PLUS instructions for use

  • English